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Abstract
We present revised diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine neoplasms (PNENs) proposed 
by the Polish Network of Neuroendocrine Tumours.
These guidelines refer to biochemical (determination of specific and nonspecific neuroendocrine markers) and imaging diagnostics (EUS, 
CT, MR, and radioisotope examination with a 68Ga or 99Tc labelled somatostatin analogue). 
A histopathological diagnostic, which determines the further management of patients with PNENs, must be necessarily confirmed by 
immunohistochemical tests. PNENs therapy requires collaboration between a multidisciplinary team of specialists experienced in the 
management of these neoplasms. Surgery is the basic form of treatment. Medical therapy requires a multidirectional procedure, and 
therefore the rules of biotherapy, peptide receptor radionuclide therapy, chemotherapy and molecular targeted therapy are discussed. 
(Endokrynol Pol 2013; 64 (6): 459–479)
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Streszczenie
W niniejszej publikacji przedstawiono zaktualizowane zalecenia dotyczące diagnostyczno-terapeutycznego postępowania w nowotworach 
neuroendokrynnych trzustki (PNEN) zaproponowane przez Polską Sieć Guzów Neuroendokrynnych.
Dotyczą one diagnostyki biochemicznej (oznaczanie specyficznych i niespecyficznych markerów neuroendokrynnych) i lokalizacyjnej 
(z uwzględnieniem EUS, CT, MR, scyntygrafii receptorów somatostatynowych z użyciem analogów znakowanych 68Ga lub 99Tc).
Duże znaczenie ma rozpoznanie histopatologiczne, które determinuje dalsze postępowanie z chorymi na PNEN i musi być potwierdzone 
badaniem immunohistochemicznym.
Terapia PNEN wymaga współpracy wielodyscyplinarnej grupy doświadczonych specjalistów zajmujących się nowotworami neuroendokryn-
nymi. Leczenie chirurgiczne jest postawową metodą postępowania. Dalsza terapia wymaga wielokierunkowego działania, dlatego omówiono 
zasady bioterapii, leczenia izotopowego, chemioterapii oraz celowanego leczenia molekularnego. (Endokrynol Pol 2013; 64 (6): 459–479)
Słowa kluczowe: nowotwory neuroendokrynne trzustki; czynne hormonalnie; nieczynne hormonalnie; diagnostyka; terapia; zalecenia
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disorders, retrograde amnesia, drowsiness, hallucina-
tions, delusions and convulsions. In approximately 12% 
of patients, loss of consciousness occurs with a grand mal 
seizure. Severe hypoglycaemia may result in death. De-
creased blood glucose level also causes increased secretion 
of catecholic amines, and therefore: paleness, increased 
perspiration, hand tremor, nausea, palpitations, hunger 
(often increased body weight) and weakness. Although 
the hypoglycaemic episodes usually occur several hours 
after a meal, often in the morning, irregularly and with 
different duration, in approximately 6% of patients hy-
poglycaemia can only occur soon after a meal [9]. They 
may be triggered by physical effort, consumption of ethyl 
alcohol or a low-calorie diet [4, 6, 7, 10–12].
A positive Whipple’s triad is helpful in diagnosing 
insulinoma:
1. Clinical symptoms suggestive of hypoglycaemia;
2. Decreased blood glucose level (< 40 mg/dL; 
2.2mmol/L) measured at the time of the symptoms;
3. Relief of symptoms after intake of carbohydrates.
Prognosis: in benign tumours — very good; in over 
95% of such patients, a surgical procedure results in 
complete recovery. In patients with distant metastases, 
mean survival is less than two years. Tumour diameter 
> 2 cm, Ki-67 > 2%, and various molecular and chro-
mosomal disorders, e.g. loss of 3p or 6q, are factors 
associated with decreased survival [6–8, 10–13].
Other tumours are classified as rare functioning 
pancreatic neuroendocrine neoplasms (RF-PNENs). They 
may occur in the pancreas and in other locations. The 
clinical symptoms associated with the presence of such 
neoplasms reflect the action of a hormone secreted by 
the tumour. In the case of very rare neoplasms, inter-
pretation of the symptoms is often ambiguous [4, 6].
RF-PNENs constitute < 10% of PNENs. In a large 
number (40–90%) of patients with RF-PNENs, hepatic 
metastases are present already at diagnosis [4, 6, 14].
VIPoma (Verner-Morrison syndrome, pancre-
atic cholera, WDHA syndrome): incidence rate 0.05–
0.2/1,000,000/year, malignant neoplasms in 40–70%, in 
ca. 3–6% associated with MEN1; location: primarily body 
of the pancreas (90%), also sympathetic nervous system, 
liver, adrenal glands. Symptoms: diarrhoea (90–100%), 
hypokalaemia (80–100%), dehydration (83%), acidosis, 
rarely skin reddening, hypercalcaemia, glucose intoler-
ance and functioning gall bladder disorders [4, 15–18]. 
Glucagonoma: incidence rate 0.01–0.1/1,000,000/ 
/year, malignant neoplasms 50–80%; in 1–20% associa-
ted with MEN1; location: body of the pancreas; symp-
toms: necrolytic erythema (67–90%), glucose intolerance 
(38–87%), weight loss (66–96%), stomatitis, diarrhoea 
and hypoaminoacidemia [4, 15–18].
Somatostatinoma: very low incidence rate, malig-
nant neoplasms > 70%, in 45% associated with MEN1, 
1. Epidemiology, prognosis/survival
1.1. Pancreatic neuroendocrine neoplasms  
(excluding gastrinomas)
The incidence of pancreatic neuroendocrine neoplasms 
(PNENs) is approximately 0.32/100,000/year. PNENs 
account for approximately 30% of all gastroentreo-
pancreatic neoplasms (GEP NENs). 45–60% of PNENs 
(in some registers up to 90%) are non-functioning. 
Despite the lack of symptoms of hormonal hypersecre-
tion, they demonstrate the ability to produce certain 
substances, e.g. pancreatic polypeptide, chromogranin 
A, neuron-specific enolase, β-hCG subunit, calcitonin, 
neurotensin and other peptides. On the other hand, 
40–55% of PNENs demonstrate excessive hormonal 
activity (functioning tumours), which is reflected in 
corresponding clinical symptoms [1–3].
Functioning PNENs include [1, 4]:
 — insulinoma — secreting insulin,
 — gastrinoma — secreting gastrin,
 — glucagonoma — secreting glucagon,
 — VIPoma — secreting vasoactive intestinal peptide,
 — PPoma — secreting pancreatic polypeptide (often 
classified as a non-functioning tumour),
 — somatostatinoma — secreting somatostatin.
Very rare functioning PNENs include: CRHoma — 
secreting CRH — hormone stimulating production of 
corticotrophin, calcitoninoma — secreting calcitonin 
and PNENs producing corticotrophin (ACTH), growth-
hormone-releasing hormone (GHRH), neurotensin, 
parathyroid hormone-related peptide (PTHrP), rennin, 
luteinising hormone (LH) and others.
The most common functioning PNENs are insulinoma 
and gastrinoma [1, 4] (discussed in detail in the section 
on gastroduodenal neuroendocrine neoplasms (NENs).
1.2. Clinical characteristics of PNEN
Insulinoma — insulin-secreting pancreatic neoplasm is 
the most common functioning neuroendocrine tumour 
of this organ. In approximately 1% of patients, an extra-
pancreatic location is possible (duodenum, stomach, 
bile ducts, lungs) [5]. Its incidence rate is estimated at 
1–3 cases/1,000,000/year. The highest incidence is ob-
served in the fifth decade of life (between the ages of 
40–45), and slightly more often in females (60%). Less 
than 10% of all tumours are malignant [4]. Insulinoma is 
usually single, and only 10% of patients have multiple 
tumours (often in multiple endocrine neoplasia type 1 
[MEN1]). In approximately 4–5% they are associated with 
MEN1 syndrome [4, 5, 7, 8]. Clinical symptoms are due 
to hypoglycaemia, not the presence of tumour (usually it 
is no more than 2 cm in diameter). They result from neu-
roglycopenia: pains and vertigo, blurred vision, double 
vision, abnormal behaviour, confusion, concentration 
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location: pancreas (55%), duodenum/small intestine 
44%, symptoms: cholelithiasis (65–90%), diabetes 
(63–90%), diarrhoea (35–90%) and weight loss [4, 15–18].
GHRHoma: unknown incidence rate, malignant 
neoplasms > 60%, location: pancreas (30%), lungs 
(54%), small intestine (7%), other (9%), associated with 
MEN1 in 16%, symptoms: acromegaly [4, 15, 16].
ACTHoma: low incidence, malignant neoplasms 
> 95%, pancreatic location (4–16%), others — extra-
pancreatic location, rarely associated with MEN1, 
symptoms: Cushing’s syndrome [4, 15, 16].
PNEN causing carcinoid syndrome: secretes 
serotonin or tachykinins, very rare: pancreatic location 
< 1%, malignant neoplasms 60–88%, rarely associated 
with MEN1, symptoms: carcinoid syndrome [4, 15, 16].
PTHrPoma: very rarely located in the pancreas, ma-
lignant neoplasms 84%, rarely associated with MEN1, 
symptoms: hypercalcaemic syndrome or, in the case of 
hepatic metastases — abdominal pain [4, 15, 16].
Prognosis: in RF-PNENs, it depends on the size of 
the tumour and the presence of distant metastases. The 
five-year survival rate in the case of advanced disease 
is estimated at 29–45%. Ki-67 > 2%, distant metastases, 
chromosomal disorders and presence of cytokeratin-19 
are unfavourable prognostics [4, 6, 13, 15, 16, 19]. 
Non-functioning pancreatic neuroendocrine 
neoplasms (NF-PNENs) do not cause characteristic 
symptoms of hormonal hypersecretion. In some 
tumours, immunohistochemical methods have re-
vealed the presence of various hormonal substances 
produced by these neoplasms, but not secreted into 
the blood circulation (or secreted in quantities which 
do not result in clinical symptoms). Most of them are 
well-differentiated tumours. Their incidence rate is 
1.8/1,000,000/year in females and 2.6/1,000,000/year in 
males. The frequency of detection increases with age, 
with the peak incidence in the 6th and 7th decades 
of life. In 3-53% (mean 19%), they are associated with 
MEN1 syndrome (the frequency is age-related, being 
higher in elderly patients) and in 13-17% with von 
Hippel-Lindau (VHL) syndrom [2, 20–23]. 
Symptoms: NF-PNENs are usually diagnosed late, 
when they are of large size, cause pressure on the 
adjacent organs or invade them, or produce distant 
metastases [2, 3]. The most common symptoms include: 
abdominal pain (35–78%), weight loss (20–35%), loss of 
appetite and vomiting (45%). Less common are internal 
haemorrhages (4–20%), jaundice (17–50%) or palpable 
tumours in the abdomen (7–40%) [2, 24–26]. Recent 
studies by Italian researchers have demonstrated that 
hepatic metastases are observed in 32% of patients 
with a newly diagnosed NF-PNEN [27]. This value 
is significantly lower compared to previous studies 
(46–73%) [21, 28–30]. 
Prognosis: The mean survival of patients with 
NF-PNENs in currently available studies is 38 months, 
with five-year survival of 43% [2, 21]. The mean survival 
of patients with distant metastases was approximately 
23 months, compared to 70 and 124 months’ survival in 
the case of a localised disease [2, 21, 31]. The histological 
grading of the tumour is also an important factor affect-
ing the length of survival [2, 32]. Other unfavourable 
prognostic factors include: age >40 years, dynamic 
development of hepatic metastases (increase of 25% of 
their volume in 6-12 months), and occurrence of osseous 
metastases [2, 33, 34].
2. Diagnostics
2.1. Biochemical diagnostics
Biochemical diagnostics of hormones and markers se-
creted by neuroendocrine neoplasms (NENs) may be 
helpful in three aspects: initial diagnosis of the disease, 
assessment of treatment efficacy, and prognosis. 
2.1.1. Non-functioning pancreatic neuroendocrine 
neoplasms (NF-PNENs)
Biochemical tests of PNENs can use chromogranin A 
(CgA), which is a marker of most NENs. On the other 
hand, the level of chromogranin B (CgB) may be el-
evated when the level of CgA is within the reference 
range [2, 35, 36].
NF-PNENs often secrete pancreatic polypeptide 
(PP). A simultaneous measurement of CgA and PP con-
centration increases the diagnostic sensitivity of PNENs 
from 74% to 90%. PP is secreted in large quantities by 
a significant group of NENs of the entire gastrointestinal 
tract (50–80% of PNENs). 
The following indicators are sometimes used in 
biochemical diagnostics of non-functioning NENs: 
neuron specific enolase (NSE) and the β subunit of 
human chorionic gonadotropin (hCG). NSE is mainly 
determined in neuroendocrine carcinoma (NEC), if 
the CgA concentration is normal.
The concentration of certain peptides, mostly insulin, 
gastrin and PP, increases significantly after meals; it may 
remain elevated for more than six hours after a meal [4]. 
Therefore, blood for the assay should be collected only 
after overnight fasting. For some markers, e.g. CgA, it is 
not necessary to collect blood under fasted conditions. 
If blood samples are not collected under fasted condi-
tions, this fact should always be mentioned to ensure the 
proper interpretation by the laboratory. Moreover, the 
blood concentrations of all NEN markers, except insulin, 
are elevated in patients with renal failure, so it is difficult 
to interpret results in such patients. Among numerous 
markers assessed in the blood, CgA is a prognostic factor 
for most NENs [37, 38, 39]. 
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2.1.2. Functioning pancreatic neuroendocrine neo-
plasms (F-PNENs)
Biochemical diagnostics of all F-PNENs requires the 
evidence of increased serum concentrations of specific 
hormonal markers (e.g. gastrin in Zollinger-Ellison syn-
drome (ZES) or insulin in insulinoma) in combination 
with clinical symptoms/Laboratory changes indicating 
the hypersecretion of an appropriate hormone, such as 
excessive secretion of gastric juice in ZES, hypoglycae-
mia in insulinoma, etc. [4]. In a great number of sporadic 
NENs, the type of cells may change and tumours may 
produce various additional peptides (apart from those 
specific for the tumour). It is related to worsening of 
the prognosis, especially when the tumour additionally 
secretes ACTH [40, 41]. 
Most insulinomas are ‘benign’ tumours with proper 
serum CgA levels which increase with metastases.
Insulinoma
The diagnosis of insulinoma is based on the following 
criteria:
 — documented glycaemia ≤ 2.2 mmol/L (≤ 40 mg/ 
/dL) and concomitant inadequate concentration of 
insulin ≥ 6 mU/L (≥ 36 pmol/L);
 — C-peptide level ≥ 200 pmol/L;
 — proinsulin level ≥ 5 pmol/L.
Interpretation of the above criteria should include 
drug-induced hypoglycaemia by verifying the serum and/
or urinary levels of sulphonylurea and its metabolites [4].
When diagnosing insulinoma, the 72-hour fasting 
test is still the gold standard, although some studies 
report that a 48-hour test may be sufficient. The fasting 
test is performed in inpatient conditions, with serial 
measurements of the blood glucose level. Patients with 
insulinoma usually develop hypoglycaemia within 
24 hours. Increased levels of ketones in urine indicate 
the proper fasting test in healthy people. In 5% of 
patients, hypoglycaemia may occur after meals [42]. 
When the symptoms of hypoglycaemia occur and the 
glucose level in the blood is ≤ 2.2 mmol/L (≤ 40 mg/dL), 
the blood should be collected for C-peptide, proinsulin 
and insulin assays. The lack of adequate suppression of 
insulin in hypoglycaemia confirms the presence of an 
independently secreting insulinoma-type tumour [4]. 
In one of the recent studies, the most sensitive cri-
terion for diagnosing insulinoma was the coexistence 
of elevated proinsulin levels and fasting glycaemia of 
≤ 2.5 mmol/L (≤ 45 mg/dL) [4].
Gastrinoma
The biochemical diagnostics of gastrinoma are discussed 
in the section on gastroduodenal NENs (pp. 444–458).
2.1.3. Rare functioning pancreatic neuroendocrine 
neoplasms (RF-PNENs)
Biochemical diagnostics of a RF-PNEN includes con-
firmation of increased serum concentrations of specific 
biochemical markers, e.g. glucagon is suspected gluca-
gonoma (positive result > 1,000 pg/mL), vasoactive 
intestinal peptide (positive result > 170 pg/mL), soma-
tostatin (positive result in pancreatic neoplasms location 
is over 50 times higher than the reference values) [34].
CgA, which is a general marker, can only be used 
to confirm the presence of a neuroendocrine neoplasm 
and monitor the course of the disease, but it cannot con-
stitute the basis for the diagnosis of functioning PNENs.
All biochemical tests should be performed during 
the first visit. Suspected Cushing’s syndrome due to 
PNEN should be confirmed by 24-hour urine or mid-
night serum cortisol measurements, or by determina-
tion of cortisol concentration in saliva. If necessary, the 
determination of cortisol with the use of the dexametha-
sone suppression test should be performed.
The assessment of markers specific for NEN is useful 
in the diagnosis and monitoring of various neoplasms 
[43], as set out in Table I. Indications for their determina-
tion depend on the clinical presentation of the patient 
with a PNEN.
2.1.4. Pancreatic neuroendocrine carcinoma (PNEC)
An assessment of the CgA levels and other hormonal 
markers in this group of PNEC usually produces nega-
tive results. NSE may be used as a marker for these 
neoplasms [34].
Minimal consensus on biochemical tests:
Determination of plasma CgA level should be the basic 
biochemical test in patients with suspected PNENs [44]. In 
non-functioning NENs, pancreatic polypeptide (PP) can 
be used for early detection of PNENs in MEN1 and PNEC 
(especially with low CgA level). 
Determination of specific markers (gastrin, insulin, 
serotonin, VIP, glucagon, etc.) should be performed if the 
patient presents symptoms suggestive of a hormonal clinical 
syndrome. Specific dynamic tests are very rarely performed. 
(*evidence level 3).
2.2. Pathomorphological diagnostics
2.2.1. Pathogenesis
The term ‘pancreatic neuroendocrine neoplasms’ refers 
to tumours arising from a pluripotent stem cell of the 
pancreatic ducts with neuroendocrine differentiation. 
The term ‘islet cell tumour’, frequently used in the 
* evidence level according to CEBM [152]
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past, is incorrect due to NEN histogenesis, as these 
neoplasms do not arise from pancreatic islets. Patho-
morphological diagnostics of NENs is based on the 
standardised WHO classification. The diagnosis is con-
firmed by immunohistochemical methods, in order to 
assess the expression of neuroendocrine markers: chro-
mogranin A and synaptophysin, and the Ki-67/MIB1 
proliferation index. Immunohistochemical examination 
of the hormonal substances produced by pancreatic 
cells is not sufficient for the diagnosis of functioning 
or non-functioning tumours [34]. Pancreatic cells may 
demonstrate immunohistochemical expression of the 
analysed products even in minimal quantities, without 
any clinical significance. 
2.2.2. Diagnostic algorithm
Histopathological diagnostics of PNENs requires an 
assessment of [45–50]:
 — histological type according to the WHO 2010 clas-
sification;
 — histological grade according to the ENETS/WHO 
2010 classification;
 — pTNM stage of clinical and pathological advancement 
(according to ENETS, AJCC/UICC of 2010) (Table II);
 — each diagnosis of NEN must be confirmed by im-
munohistochemical examinations with the use of 
antibodies against chromogranin A and synapto-
physin, and by the Ki-67/MIB1 proliferative activity 
assessment;
 — in certain cases, products secreted by NENs, such 
as gastrin, insulin or glucagon may be assessed. 
These markers are more useful for detection of the 
metastases of functioning tumours, especially if the 
original site is unknown. Clinical staging of NENs 
is presented in Table III.
Classification of NENs according to WHO 2010 
and the histological grade of NETs according to the 
standardised ENETS/WHO 2010 system are presented 
in the section on general recommendations for the 
management of GEP NENs (pp. 418–443).
Table I. Specific markers for various PNENs (modified according to [34, 43])
Tabela I. Specyficzne markery dla różnych PNEN (zmodyfikowane wg [34, 43])
Tumour type  Laboratory tests Expected results
All pancreatic NENs CgA Increased concentration only in metastatic tumours
Non-functioning NENs PP, NSE, hCG Increased concentration
Insulinoma CgA, insulin, glucose, 
C-peptide or proinsulin
Inadequate increase in the insulin/glucose concentration ratio
Increased concentration
Gastrinoma Gastrin Increased concentration
Glucagonoma Glucagon, enteroglucagon Increased concentration
VIPoma VIP Increased concentration
Somatostatinoma SST Increased concentration
PPoma PP Increased concentration
MEN1 CgA, gastrin, calcium, PTH, insulin, 
glucagon, PP, PRL
Increased concentration of selected markers
CgA — chromogranin A; CgB — chromogranin B; hCG — human chorionic gonadotropin; 5-HIAA — 5-hydroxyindoleacetic acid; NSE — neuron specific enolase;  
PP — pancreatic polypeptide; PTH — parathyroid hormone; SST — somatostatin; VIPoma — tumour secreting vasoactive intestinal peptide; PRL — prolactin
Table II. ENETS and TNM UICC/AJCC classification, 2011
Tabela II. Klasyfikacja TNM ENETS i AJCC/UICC, 2011
Feature T according to TNM TNM ENETS TNM AJCC/UICC, 2011
T1 Tumour limited to the pancreas, < 2 cm in diameter Tumour limited to the pancreas, < 2 cm in diameter
T2 Tumour limited to the pancreas, 2–4 cm in diameter Tumour limited to the pancreas, > 2 cm in diameter
T3 Tumour limited to the pancreas, > 4 cm in diameter or 
invading duodenum or bile tract
Tumour invading the adjacent tissues, without invasion 
of the main vascular trunks (coeliac axis, superior 
mesenteric artery)
T4 Invasion of the adjacent organs or the wall of large vessels Invasion of the wall of large vessels
464
Pancreatic neuroendocrine neoplasms  Beata Kos-Kudła et al.
2.2.3. Prognostic factors in the histopathological report
In the histopathological examination, it should be noted 
that nodules smaller than 5 mm are referred to as micro-
adenoma, and are not considered in the histopathologi-
cal report. Multiple foci are characteristic for PNENs, 
especially in MEN1, in over 30% of gastrinoma cases 
and 13% of insulinoma cases. Therefore, a very careful 
microscopic assessment of the surgical material, involv-
ing cross-sections of the pancreatic parenchyma at 3 to 
5 mm intervals, is necessary. In each case, an assessment 
of resectability is an important prognostic parameter. 
In order to perform it, it is necessary to evaluate mac-
roscopically and microscopically the surgical margins: 
transpancreatic, retroperitoneal and radial, created by 
the posterior wall of the surgical material. Assessment of 
the vascular and neural invasion is also recommended, 
as according to certain clinical studies it is associated 
with lymph nodes metastases and shorter life expec-
tancy. Coagulative necrosis, local or geographic, is 
another prognostic factor, as it correlates with a high 
grade of histological malignancy of the tumour.
The morphological picture of the tumour, com-
prising tumour tissue architecture and characteristics 
of its cells, is also reflected in the tumour differ-
entiation stage [51, 52]. Under a light microscope, 
PNEN usually corresponds to a well-differentiated 
neuroendocrine neoplasms G1 or well-differentiated 
neuroendocrine neoplasms G2. Organoid structures 
in the form of solid nests, trabecular or labyrinthine 
systems, or structures resembling glands and rosettes, 
are characteristic. They are accompanied by a vary-
ing quantity of tumour stroma and numerous blood 
vessels surrounding the tumour nests. It is worth 
emphasising that amyloid deposits are typical for 
a functioning tumour such as insulinoma, whereas 
glandular-like structures and psammomatous bodies 
are characteristic of somatostatinoma. The charac-
teristics of neuroendocrine neoplasm cells are well 
known to differ from other neoplasms. They are small 
or medium-sized, with acidophilic or amphophilic 
and granular cytoplasm. The nuclei are round or 
oval, usually situated centrally in the cell. A typical 
feature of a NEN, which helps to distinguish it from 
adenocarcinoma, is fine-grained chromatin, referred 
to as ‘salt and pepper ’. Apart from the above typi-
cal features of neuroendocrine tumours, their cells 
may present a different picture, creating oncocytic, 
clear cell, fat-rich and rhabdo-like variants. PNENs 
may then resemble melanoma, clear cell renal cell 
carcinoma or adrenal cortical carcinomas. Diagnostic 
errors are caused by incorrect differentiation between 
a PNEN and a pancreatic ductal adenocarcinoma 
or acinocellular carcinoma, or clear cell carcinoma 
metastases from other organs.
To sum up, pathomorphological diagnostics of 
pancreatic NENs requires experience on the part of 
the pathomorphologist, co-operation of an interdisci-
plinary team of specialists, and access to an immuno-
histochemical laboratory.
Minimal consensus on pathology
Minimal histopathological report for a PNEN should include:
 — histological type of the neoplasm, considering the divi-
sion into well-differentiated neuroendocrine neoplasms 
(NEN), neuroendocrine carcinomas (NEC) and mixed 
neoplasms (MANEC);
 — histological G grading referring to well-differentiated 
neoplasms (NEN G1, NEN G2);
 — pTNM staging according to ENET and AJCC/UICC 
classifications (it is important to provide affiliation of the 
classification in each case);
 — assessment of surgical margins.
Histopathological diagnosis of NEN must be necessarily 
confirmed by immunohistochemical tests assessing expres-
sion of the neuroendocrine markers: synaptophysin and 
chromogranin A, as well as the Ki-67 proliferative activity 
using the MIB1 antigen [53] (*evidence level 3).
2.3. Imaging diagnostics 
2.3.1. Endoscopic diagnostics
Classical gastrointestinal endoscopy is practically of no 
importance for the diagnostics of PNENs.
2.3.2. Ultrasonography
Transabdominal ultrasonography
The sensitivity of conventional ultrasonography (USG), 
mostly performed as the first-line examination in the 
detection of primary tumours, and in assessment of 
the staging of the disease, is low for small tumours. On 
Table III. Clinical staging of PNENs 
Tabela III. Stopień klinicznego zaawansowania PNEN
Clinical stage Comments
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1-3 N1 M0
Stage III T4, any N M0
Stage IV Any T, any N M1
* evidence level according to CEBM [152]
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average, ultrasonography detects approximately 30% 
of primary insulinomas and gastrinomas. The sensiti-
vity of this method increases for detection of hepatic 
metastases, when it amounts to 50–80%. For larger 
tumours, mostly non-secreting pancreatic tumours 
and late-diagnosed glucagonoma, the sensitivity of 
transabdominal USG is higher [54, 55, 56].
2.3.3. Endoscopic ultrasonography
Endoscopic ultrasonography (EUS) enables precise im-
aging of the pancreas, and it is the most sensitive of the 
methods presently used in the diagnostics of pancreatic 
focal lesions (it detects lesions of 1–2 mm in diameter); 
normal results of EUS practically exclude the presence of 
a pancreatic tumour [57]. EUS imaging is useful when the 
CT scan image is inconclusive. Biopsy is recommended to 
confirm the neoplastic character of the lesion [58].
EUS enables the ability to:
 — localise functioning neoplasms (diagnosed on the 
basis of clinical and/or biochemical symptoms);
 — obtain the material for histopathological examination;
 — tattoo small focal lesions before the planned surgi-
cal treatment;
 — perform diagnostic imaging of non-functioning 
PNENs;
 — conduct screening tests in patients with MEN1.
In the case of small insulin-secreting tumours, the 
EUS sensitivity is up to 94% [59–64]. Tumour location in 
the tail of the pancreas or the presence of small, slightly 
hypoechogenic nodules located deep into the pancreatic 
parenchyma and multifocal nodules can be a limitation 
for EUS [59, 65]. According to the literature, in the case 
of tumours in the pancreatic tail, the sensitivity of the 
examination can decrease to 60%. Diagnostic sensitivity 
of the examination in pancreatic gastrinoma tumours is 
nearly 100%, but it decreases in the case of multifocal le-
sions and those with an extra-pancreatic location; in the 
case of gastrin tumours located in the duodenum and 
outside the pancreatic parenchyma, the sensitivity of the 
test is estimated to be approximately 50% [63, 66]. 
EUS is also important in the differential diagnostics 
of PNENs of ambiguous character, and in pre-operative 
assessment of the neoplasm stage. There are certain 
specific ultrasonographic characteristics which allow 
differentiation between pancreatic carcinomas and 
neoplasms of the neuroendocrine origin, as well as be-
tween functioning and non-functioning neoplasms [67]. 
The usefulness of EUS for the assessment of the stage 
of lesions has also been confirmed, particularly for the 
evaluation of vascular invasion [68].
EUS is also used to perform fine-needle biopsy 
through the stomach wall. It is believed that this route 
of access, compared to percutaneous biopsy, reduces 
the danger of the spreading of neoplastic cells. In the 
study by Voss et al. [69], the diagnostic accuracy of 
such biopsy for pancreatic carcinoma was 81%, and for 
PNEN was 46.7%.
Presently, third generation contrast agents are 
entering ultrasound imaging. These agents are com-
posed of gas microbubbles in a phospholipid shell, 
characterised by a long half-life in the bloodstream and 
enhanced, perfusion-dependent greyscale. Currently, 
studies are conducted on the use of contrast enhanced 
ultrasound (CEUS) for the differential diagnostics of 
pancreatic tumours, including PNENs [70]. CEUS 
detects tumours smaller than 2 cm in diameter with a 
sensitivity comparable to EUS (95%). With respect to 
PNENs, the method’s sensitivity is up to 94%, specific-
ity reaches 96%, the positive predictive value — 75%, 
and the negative predictive value is up to 99%. The 
image of neuroendocrine neoplasms has a character-
istic echo pattern after intravenous administration of 
the contrast agent: in the arterial phase, echogenicity 
increases intensively and quickly decreases as the 
contrast agent washes out in the venous phase [2]. 
The highest accuracy in the differential diagnosis of 
pancreatic neoplasms and in detection of small (less 
than 1 cm) lesions is achieved by combining the EUS 
technique with intravenous administration of the 
contrast agent (Contrast-Enhanced Harmonic Endoscopic 
Ultrasonography, CH-EUS) [71]. 
In pre-operative diagnostics, it is possible to inject 
ink into the tumour tissue during EUS, which enables 
faster intraoperative location of the lesion. Using this 
method is important, especially in the case of laparo-
scopic procedures, during which it is impossible to 
palpate the pancreatic lesions. Apart from that, precise 
location of the lesion enables the ability to achieve an 
adequate resection margin and to preserve healthy 
pancreatic tissue. However, it is worth emphasising that 
tattooing may cause acute pancreatitis [72, 73].
A special indication for conducting EUS examina-
tion is MEN1. The incidence of pancreatic lesions in 
this group of patients is estimated as 40–80%. Although 
functioning neoplasms can be early diagnosed due 
to typical clinical and biochemical symptoms, non-
functioning neoplasms (ca. 50% of lesions) in most 
patients are diagnosed late, which determines a poor 
prognosis. EUS is recommended as the most sensitive 
and economically justified method of monitoring these 
patients, as early detection of a pancreatic lesion enables 
the implementation of radical treatment.
2.3.4. Intraductal ultrasonography
Intraductal ultrasonography (IDUS) may surpass EUS 
in the detection of PNENs. In this method, a probe of 
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2 cm in diameter is introduced into the duct of Wirsung 
through the duodenoscope channel.
2.3.5. Intraoperative ultrasonography
The sensitivity of intraoperative ultrasound (IOUS) in 
the detection of small PNENs is similar to that of EUS. 
The sensitivity of this examination, combined with 
intraoperative palpation assessment, is up to 97%. In 
the case of gastrinoma, the sensitivity of the test within 
the pancreas is close to 100%, but decreases to 58% with 
extra-pancreatic location. IOUS also allows detection of 
multifocal tumours and metastases in the liver. IOUS 
examination is also performed during laparoscopy [74]. 
2.3.6. Computed tomography (CT) and magnetic 
resonance imaging (MR)
Presently, according to current guidelines, a spiral 
multidetector CT (MDCT) and MR imaging are used for 
the diagnosis of parenchymal abdominal organs. These 
methods are especially important in the assessment of 
the stage of the neoplastic disease, and in monitoring 
of the response to treatment [75]. They are also useful 
for the assessment of anatomical location and resect-
ability of the primary lesion. Computed tomography 
enables performing a targeted biopsy from the lesion. 
The sensitivity of each imaging method depends on the 
location and type of tumour [64, 76]. 
Prior to administration of the contrast agent, func-
tioning PNENs are usually isodense, rarely hypodense 
compared to the remaining pancreatic parenchyma, 
and calcifications are clearly visible. Most tumours are 
richly vascularised (insulinoma 80%), so in the arte-
rial phase, MDCT is intensively enhanced. Metastases 
demonstrate a similar behaviour. Therefore, the MDCT 
examination should cover both pancreas and liver in 
the arterial phase. In this phase of the test, it is also 
possible to assess the tumour/coeliac arteries relation. 
In the parenchymal phase, the assessment is limited to 
the pancreas, and it concerns tumour morphology and 
the level of contrast washing out. The portal venous 
phase again comprises the pancreas, liver and hepatic 
portal system [77]. 
Some researchers have suggested conducting the 
examination also in the delayed phase (150 seconds 
after the administration of the contrast agent), and in 
order to further assess the level of washing out of the 
contrast material from the tumour. In typical neuroen-
docrine neoplasm, the contrast enhancement should 
decrease in the delayed phase relative to the arterial 
phase by at least 60 HU. Other types of enhancement 
in PNEN include uneven washout of the contrast agent 
(from more than half or from less than half of the tu-
mour mass), or slowly increasing enhancement when 
the tumour is better visible in the equilibrium phase, 
in which the uptake in the normal pancreatic paren-
chyma decreases. This is a behaviour characteristic for 
tumours with a high connective tissue content. In the 
parenchymal and secretive phase, neuroendocrine 
neoplasms are not always isodense and are therefore 
invisible in the CT scan. Certain neoplasms in these 
phases of examination maintain the enhancement or 
only begin the process of collecting the contrast agent. 
Slightly enhanced neoplasms are usually poorly dif-
ferentiated, so the level of enhancement correlates with 
the length of patient survival [78, 79]. Non-functioning 
neoplasm demonstrate a lower enhancement after 
the administration of the contrast agent, and are het-
erogeneous due to the necrotic areas. Calcifications in 
adenocarcinomas are very rare, whereas in functioning 
and non-functioning PNENs they are found in at least 
25% of cases. In larger tumours, the pancreatic duct 
is dilated, and parenchymal atrophy is observed. The 
only features that distinguish malignant lesions from 
benign ones are invasion of the adjacent structures and 
distant metastases. Hepatic metastases are detected in 
the arterial phase of the examination [76]. 
Due to shortened time of scanning, a reduced 
number of movement artifacts, and obtaining thin (1–2 
mm) tissue layers, MDCT enables multi-dimensional 
and spatial reconstructions, which facilitates imaging 
of structures smaller than 1 cm, and allows a complete 
assessment of the vascular invasion of the tumour [80]. 
The sensitivity of contrast-enhanced MDCT using 1 mm 
layers in diagnosis of insulinoma reaches 85–94% [81, 
82], whereas for various types of NENs the sensitivity 
of multidetector CT is 50–90%, and the specificity is 
96% [2, 83, 84]. 
The role of CT scans in the assessment of PNEN con-
sists in the description of tumour morphology with pre-
cise location, and, with reference to organ-transgressing 
infiltration, in determination of the adjacent fat tissue 
invasion, infiltration of the duodenum, common bile 
duct, stomach, spleen, intestinal loops, adrenal glands, 
as well as determination of arterial and venous inva-
sion, providing information about the invaded part and 
length of the vessel. The description should also con-
tain information concerning enlarged regional lymph 
nodes and the assessment of the liver for metastases. 
Assessment according to TNM classification should be 
possible on the basis of CT description [1].
MR conducted according to the optimal protocol 
has a similar sensitivity in the diagnosis of PNEN as CT, 
which is up to 80–90%. MR offers a higher tissue resolu-
tion in combination with multi-dimensional imaging. 
Limitations of this method include: reduced availability 
(compared to CT scanning), higher price, longer dura-
tion of examination and the necessity of co-operation 
with the patient. The method is recommended espe-
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cially for younger patients, as it does not require the use 
of ionising radiation, and also in patients whose CT scan 
image is inconclusive. Neuroendocrine neoplasms are 
hypointense on T1-weighted images, and hyperintese 
on T2-weighted images. Intravenous administration of 
the contrast agent increases sensitivity of the method 
[77]. In a multi-phase examination following the intra-
venous administration of the contrast agent, the images 
are enhanced according to the CT enhancement pat-
tern provided above. In addition, in MR spectroscopy, 
which uses the chemical shift displacement, it is pos-
sible to determine the chemical composition of tissues. 
A relatively increased lipid content in NENs facilitates 
differentiation in uncertain cases.
In recent years, a diffusion weighted imaging 
(DWI) method has also been used, in which the level 
of water diffusion limitation in the tissue is assessed. 
Neuroendocrine neoplasms, particularly those with 
a high connective tissue content, cause limitation of 
the diffusion of water molecules, which generates an 
intensive signal in the DWI sequence, accompanied by 
lowered ADC. DWI is particularly valuable in tumours 
with a significant connective tissue component, which 
are poorly or atypically enhanced after intravenous 
administration of the contrast agent [54, 85]. 
2.4. Radioisotope diagnostics 
The recently observed development of diagnostic meth-
ods with the use of labelled somatostatin analogues in 
examinations using the technique of single proton emis-
sion computed tomography (SPECT/CT) and positron 
emission tomography (PET/CT), also in combination 
with intraoperative detection with the use of isotope 
probe, contributes to higher detection rates of PNENs 
and their metastases. These tests can identify lesions 
undetected by anatomical imaging methods, increasing 
the chances of locating the primary focus and determin-
ing the actual stage of the neoplasm [76, 86]. They may 
also be the first-line method in the diagnostics of early 
recurrence, in monitoring the disease and in choosing 
the optimal treatment. A positive result of receptor 
scintigraphy is also the basis for introducing therapy 
with ‘cold’ and/or ‘hot’ (bound to a radioactive isotope) 
somatostatin analogues (SSA) [87, 88]. 
111In-Octreoscan, used until recently in scintigraphic 
diagnostics, has been substituted in Poland with 99Tc-
EDDA/HYNIC-Tyr(3)-octreotide. The sensitivity of 
somatostatin receptor scintigraphy (SRS) for tests with 
the use of 111In-Octreoscan in the diagnosis of the pri-
mary lesion for various PNENs has been estimated at 
70–100% for gastrinoma, VIPoma and glucagonoma 
[89], at 50–60% for insulinoma [86], and at ca. 90% 
for non-functioning tumours. Scintigraphy with the 
use of 111In-Octreoscan enables the ability to detect 
approximately 90% of GEP NENs hepatic metastases 
[90]. Generally, the sensitivity of SRS is estimated to be 
71–96% [91], whereas the specificity ranges between 
76% and 95% [89, 91]. Using the SPECT technique sig-
nificantly improves the sensitivity of the method [89]. 
The usefulness of increasingly popular somatostatin 
analogues labelled with technet 99m for the diagnostics 
of PNENs has been confirmed by many authors [87, 92]. 
99mTc-EDDA/HYNIC-Tyr(3)-octreotide (99mTc-EDDA/
HYNIC-TOC) 99mTc-[99mTc-EDDA/HYNIC]octreotate 
demonstrates a higher uptake by the pancreatic and pi-
tuitary tumour cells having somatostatin receptors than 
octreotide. The possibility of combining scintigraphic 
and tomographic images with the use of fusion image 
SPECT/CT enables a precise detection of the anatomi-
cal location of the lesion visible in molecular imaging, 
and contributes to increased diagnostic sensitivity and 
specificity [93]. 
Presently, the most sensitive examination in the 
diagnostics of well-differentiated NENs is definitely 
the PET/CT test with the use of somatostatin analogues 
(SSA) labelled with 68Ga: DOTA-TOC, DOTA-TATE 
and DOTA-NOC, and in the future probably also with 
64Cu-TETA-octreotide [94]. In the diagnostics of PNENs, 
it is also possible to use the PET/CT test with the use 
of 18F-FDOPA. The usefulness of 18F-FDOPA has been 
evaluated in different types of NENs and at different 
stages of the neoplastic process. Becherer et al. dem-
onstrated a higher diagnostic sensitivity of 18F-FDOPA 
PET compared to SRS and CT scanning in patients with 
advanced NENs, both with regard to staging and in 
the diagnostics of osseous metastases. However, SRS 
proved superior in planning treatment with SSA [95]. 
The examination with 18F-FDOPA enables the exclu-
sion of artifacts related to physiological activity in the 
peripancreatic tissues [44]. Other studies comparing 
68Ga with 18F-FDOPA have indicated the indisputable 
superiority of the 68Ga-DOTA-TATE test in the detec-
tion and staging assessment of NENs, whereas PET/ 
/CT examination with 18F-FDOPA should be performed 
when the test with gallium is negative [96]. In the case 
of insulinoma, the diagnostic value of 18F-FDOPA is 
disputable [97]. Another tracer used in diagnostics of 
PNENs is 11C-5-hydroxytryptophan (5-HTP) [2]. It is 
not used in Poland. 18F-Fluorodeoxyglucose (FDG) is 
used in the diagnostics of fast-growing and aggressive 
PNENs and PNECs with a poor prognosis. 
The next step to improve sensitivity of location diag-
nostics of small PNETs (gastrinoma, insulinoma) is using 
an intraoperative radioisotope probe (RGS) [98, 99].
In recent years, new diagnostic tracers for PNENs 
have been introduced. They enable the location of 
certain types of functioning tumours, and due to di-
agnostic effectiveness in the future they may become 
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important imaging tools for PNENs. One of them is 
a labelled analogue of glucagon-like peptide-1 (GLP-1). 
Due to a very high expression of receptors for GLP-1 in 
some neoplasms (in 100% of benign insulin-secreting 
tumours), scintigraphy with the use of labelled GLP-1 
analogues may become a diagnostic method competing 
with SRS [100]. Several reports concerning imaging of 
insulinoma on animal models and in humans have been 
published. A high tracer uptake by this tumour was 
demonstrated (high tumour/background ratio), and the 
quality of the received image was assessed as very good. 
Using a GLP-1 analogue labelled with 111In, insulinoma 
implanted in a mouse was completely destroyed. In 
the study, the GLP-1 analogues labelled with 111In (e.g. 
[Lys40(Ahx-DOTA-111In)NH2]-Exendin-4), 99mTc 
([Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4) 
and 68Ga were used. Preliminary study results indi-
cate a lack of receptor expression for GLP-1 in most 
malignant forms of insulinoma (positive SRS is more 
common in these cases), which suggests the usefulness 
of imaging with labelled GLP-1 analogues for the dif-
ferentiation of benign and malignant insulin-secreting 
tumour forms [101, 102].
2.5. Location diagnostics of different PNENs
2.5.1. Insulinoma 
Most frequently they are small tumours, less than 2 cm 
in diameter (60–70% of cases), usually classified as group 
1 according to the WHO classification; they are mostly 
single (85%) and located in 99% of cases in the pancreas, 
with a similar prevalence for all parts of the organ [10]. 
While conducting location diagnostics in the search for 
the cause of hypoglycaemia with hyperinsulinism, it 
should be noted that in approximately 4% of cases, the 
reason is hyperplasia of β cells (nesidioblastosis; NIPHS, 
noninsulinoma pancreatogenous hypoglycaemia). In 
the case of insulinoma, the most sensitive imaging ex-
aminations include endoscopic ultrasonography (EUS) 
and intraoperative USG. The usefulness of classical 
USG, EUS, IOUS, CT and MRI is discussed in detail 
in the section concerning the imaging diagnostics of 
PNENs. 
Another test used in the diagnostics of insulinoma is 
SRS. It is important to note that only 50-60% of insulino-
ma tumours demonstrate somatostatin receptor expres-
sion (according to the literature data, the frequencies of 
expression for different SSTR types in insulinoma are as 
follows: SSTR1 — 51%, SSTR2 — 69%, SSTR3 — 62%, 
SSTR4 — 39%, and SSTR5 — 66%) [86]. If the results of 
other imaging tests are negative, a PET/CT scan with 
68Ga-somatostatin analogue may be performed [4]. 
Transhepatic portal venous insulin sampling (THPVS) 
and angiography with a selective calcium stimulation 
test [103] are very rarely used in diagnosing insulinoma. 
The methods are practically used only when other 
imaging techniques do not enable the locating of the 
focal lesion [10]. In the near future, GLP-1 analogue 
will probably play an important role in the diagnostics 
of hardly detectable, small insulinomas, due to GLP-1 
receptor expression in all tumours of this type. 
2.5.2. Gastrinoma
Gastrinoma is found mostly within the triangle: pancre-
atic head — duodenum — hepatic hilum. In 48–60% of 
cases, lymph nodes and hepatic metastases are present 
at the diagnosis, but in some groups of patients, the 
proportion of malignant neoplasms is up to 90% [104]. 
Multifocal lesions are also possible. The usefulness of 
USG, EUS, intraoperative USG, IOUS, CT and MRI 
examinations is presented in the section concerning 
the imaging diagnostics of PNENs. 
Other examinations used for the diagnostics of 
gastrinoma include:
 — somatostatin receptor scintigraphy (SRS). According 
to different authors, the sensitivity of gastrinoma 
detection ranges between 50% and 100% (according 
to the literature data, the frequencies of expression 
for different somatostatin receptors (SSTR) types 
are as follows: SSTR1 — 71%, SSTR2 — 50%, SSTR3 
— 92%, SSTR4 — 78%, SSTR5 — 81%) [105]. SRS is 
the best examination to assess the early stages of the 
disease and the presence of distant metastases, but 
sensitivity of the test decreases to 50% if the tumour 
is smaller than 1 cm [4];
 — intraoperative radioisotope probe. This method 
improves the sensitivity of detection of pancreatic 
primary lesions and metastases to the surrounding 
lymph nodes and to the liver;
 — in the diagnostics of gastrinoma, scintigraphy with 
the GLP-1 analogue may also be used, due to the 
GLP-1 receptor expression in this tumour. 
In the location diagnostics of small tumours, the 
combined use of a few diagnostic methods seems 
reasonable. In certain cases also performing angiog-
raphy (the sensitivity of angiography is estimated 
at 30-50%) with venous catheterisation (AVSV) may 
be considered. In the case of gastrinoma located in 
the duodenum, intraoperative transluminescence is 
also used.
2.5.3. Location diagnostics of glucagonoma,  
VIPoma, somatostatinoma, non-functioning  
tumours and ACTHoma
At the moment of diagnosis, glucagonoma, somatostati-
noma and NF-PNETs are usually large (approximately 
5–6 cm), whereas VIPoma is slightly smaller (ca. 2 cm). 
The lesions are usually diagnosed late, and in approxi-
mately 70–90% of cases metastases are found already at 
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the diagnosis [16, 105]. Due to the size of lesions, they 
are easier to find by means of classical imaging methods 
(USG, CT, MRI). SRS, whose diagnostic sensitivity is 
70–100%, is a standard examination in the assessment 
of the primary lesion, clinical staging (detection of 
metastases to the liver, lymph nodes, adrenal glands, 
spine), and in qualification for receptor radiotherapy 
[16, 86]. SSTR1 and SSTR2 expression is observed mostly 
in glucagonoma, SSTR5 in somatostatinoma, SSTR2 in 
VIPoma, and SSTR1, SSTR2, SSTR3 and SSTR5 in non-
functioning neoplasms. Rare ACTHoma neoplasms 
also demonstrate somatostatin receptor expression. In 
the case of RF-PNENs, EUS is not recommended as the 
first-line procedure, but it may be used when MDCT, 
MRI and SRS-SPECT results are inconclusive. EUS may 
be useful in pre-operative diagnostics, whereas it is 
rarely necessary in patients with hepatic metastases [4]. 
2.5.4. Pancreatic endocrine carcinomas (PNECs)
In the location diagnostics of poorly differentiated 
PNECs and their metastases, all imaging examinations 
may be used: USG, CT, MRI, 18F-FDG PET, as well as 
SRS in tumours with overexpression of somatostatin 
receptors.
Summary of the diagnostics of PNENs
In the diagnostics of PNENs, both classical imaging 
techniques and nuclear medicine tools are used. The 
basic examination for patients with a PNEN is EUS, 
which enables location of the primary tumour site. 
Another examination is the SRS with 68Ga or 99Tc-DOTA 
TOC, which enables location of the primary lesion, but 
also assessment of the stage of the disease and qualifica-
tion for treatment with ‘hot’ SSA. CT or MRI are next 
in the diagnostics of PNENs; their main role consists 
in the assessment of the stage of the disease. A PET/CT 
scan with 18FDOPA may be an alternative diagnostic 
method if SRS results are negative. In the diagnostics 
of insulinoma, the role of a new isotope-labelled GLP-1 
analogue is widely discussed. 
Minimal consensus on imaging
The main examinations recommended in the diagnostics of 
PNENs include: EUS, CT, and MR, and next a radioisotope 
examination with a labelled somatostatin analogue (68Ga or 
99Tc-DOTA TOC PET/CT,SPECT/CT) (*evidence level 3). 
3. Treatment of PNENs
3.1. Surgical treatment
Surgical treatment is the therapy of choice in the case of 
PNENs, as it is associated with significantly prolonged 
patient survival [2]. The development of diagnostic 
methods has improved the detection of small, asymp-
tomatic tumours. Most non-functional neoplasms 
of ≤  2  cm in diameter are benign and demonstrate 
a moderate risk of becoming malignant. Only 6% of 
non-functional, accidentally diagnosed PNENs present 
histopathological characteristics of malignancy [2]. In 
certain cases, tumours of ≤ 2 cm in diameter diagnosed 
accidentally may be observed for the first year, per-
forming tests at three-month intervals, then every six 
months for the next three years [2]. Due to the lack of 
clear recommendations, the decision on the course of 
treatment should be taken by a multidisciplinary team 
of doctors experienced in the management of PNENs 
(*evidence level 4). When choosing surgical treatment, 
it is necessary to consider short-term and long-term 
effects of this therapy. According to the WHO classifica-
tion, there is a correlation between the tumour size and 
its potential malignancy. Tumours of > 2 cm require an 
extensive surgery (*evidence level 3) [44]. 
In multiple endocrine neoplasia type 1 (MEN1), if 
multiple lesions occur, it is recommended to remove 
them preventively before they become malignant; how-
ever, this approach in the case of small, non-functional 
neoplasms is still controversial (*evidence level 3) [2]. In 
all cases, an intraoperative USG examination is recom-
mended. The presence of multiple tumours sometimes 
requires a whole-organ resection. It is known that non-
functional neoplasms associated with MEN1 should 
be removed if they are larger than 2 cm in diameter, 
fast-growing (annual growth of > 0.5 cm), and if me-
tastases occur [2].
The type of surgical treatment of PNEN depends on 
its size, location, invasion of the adjacent organs, pres-
ence of distant metastases and the level of tumour ma-
lignancy, patient’s general condition and the ability to 
control the clinical symptoms (*evidence level 4). Patients 
are qualified for a radical or palliative treatment, which 
only improves the quality of life (*evidence level 4). In 
the case of tumours located in the head of the pancreas, 
pancreatoduodenectomy is performed, whereas in tu-
mours located in the body or tail of the pancreas, distal 
resection is conducted, with or without splenectomy 
(*evidence level 4). In certain cases of small and well-de-
marcated PNENs (non-functional neoplasms and insu-
linomas < 2 cm), atypical resections may be performed, 
including enucleation and resection of the middle seg-
ment (*evidence level 3) [106]. Resection of the middle 
segment is performed only in the case of small lesions 
located in the pancreatic body. The condition of tumour 
enucleation is continuity of the duct of Wirsung [2]. 
* evidence level according to CEBM [152]
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Resection is necessary if the tumour is located < 3 mm 
from the pancreatic duct [4]. Enucleation of the lesion 
entails the risk of damaging or closing the duct of 
Wirsung, which is associated with complications [107]. 
These include acute postoperative pancreatitis and 
pancreatic fistula. Apart from the above complications, 
resection of a large part of the pancreas may cause the 
symptoms of exocrine and endocrine pancreatic insuf-
ficiency [108]. In certain cases, it is possible to conduct 
central pancreatectomy with a Roux-en-Y anastomosis 
of the pancreatic tail with a loop of the small intestine, 
and closing off the body of the pancreas.
Tumour resection should be considered even in the 
presence of metastases, including hepatic metastases, 
if they are potentially resectable, and the patient meets 
the criteria for the surgery (*evidence level 4) [1, 44]. As 
PNENs are often malignant, it is necessary to remove 
the regional lymph nodes during resection (*evidence 
level 3) [1, 108, 109]. In the case of enucleation and re-
section of the middle segment, it is also recommended 
to remove lymph nodes for histopathological examina-
tion [2, 107]. It is generally believed that PNECs should 
not be operated if disseminated metastases have been 
found in the diagnostic process (*evidence level 3) [1].
Surgical treatment intended to remove the tumour 
(in the case of a resectable tumour) or reduce its mass 
(palliative therapy) in patients with disease limited to 
the primary tumour and regional lymph nodes should 
be standard procedure (*evidence level 4) [44]. Resection 
should be performed only in those centres specialising 
in surgery of the pancreas. Laparoscopic resection of 
the pancreas is increasingly common, but the decision 
concerning whether to use an ‘open’ or a laparoscopic 
method should be taken by a pancreatic surgery spe-
cialist in the referential centre (*evidence level 3). Distal 
resections and laparoscopic enucleation of pancreatic 
tumours are presently considered to be safe [2]. In the 
case of a PNEN, an intraoperative USG examination is 
recommended.
The most common functional neoplasms are insu-
linoma and gastrinoma, while other tumours are rare 
RF-PNENs [4]. Gastrinoma is most often located in 
the head of the pancreas; in 60–90% it is a malignant 
neoplasm, and due to a frequent invasion of the lymph 
nodes, there are indications for regional lymphadenec-
tomy [14]. It is recommended to remove the lesion radi-
cally to prevent hepatic metastases, which considerably 
worsen the prognosis. The scope of procedures depends 
on the tumour location and size, and comprises enuclea-
tions, resections of the middle segment, distal resections 
and pancreatoduodenectomies [109]. Laparoscopic 
procedures are not recommended [4]. In Zollinger-
Ellison syndrome (ZES), which may be associated with 
MEN1 syndrome, surgical treatment is indicated if the 
tumour is larger than 2 cm. This approach is intended 
to prevent metastases [44] (*evidence level 3). Pancrea-
toduodenectomy is the recommended procedure (for 
tumours located in the head of the pancreas), as less 
extensive procedures are associated with recurrence 
in 90% of cases [4, 14]. 
Insulinomas are in 90% of cases benign; their re-
moval does not require regional lymphadenectomy 
and where there is precise preoperative localisation of 
the tumour, laparoscopy is effective [110]. In the case of 
a suspected malignant insulinoma, or recurrence of the 
tumour, radical treatment is recommended, including 
excision of the recurrence and the possible hepatic me-
tastases [4]. RF-PNEN include: VIPoma, glucagonoma, 
somatostatinoma, GRHoma and ACTHoma. In this 
group of tumours, radical surgical treatment is recom-
mended even if hepatic metastases occur, and the scope 
of resection and lymphadenectomy corresponds to the 
procedures implemented in gastrinoma. Laparoscopic 
procedures are not recommended (*evidence level 3) 
[1, 4]. 
In advanced F-PNENs, resection is intended to 
reduce the symptoms and the tumour mass. Cytoreduc-
tion may be considered if removal of 90% of the tumour 
mass is possible, even if hepatic metastases are present. 
Removal of 90% of the visible tumour mass is possible 
in only 5–15% of cases [14, 111]. R1 resections of PNENs 
are not associated with a worse survival rate than R0 
resection [107]. Cytoreduction may be performed with 
radiofrequency thermoablation (RFA) (*evidence level 
3), which can also be conducted laparoscopically. This 
method may be used if there are fewer than ten focal 
lesions in the liver, and if the largest one is < 5 cm in 
diameter (optimally 3 cm). This method enables the 
control of symptoms in over 90% of patients [112].
Radical excision of hepatic metastases is the ‘gold 
standard’ in the therapy of advanced PNENs, therefore 
resection should be performed whenever it is possible 
(*evidence level 4). The method of resection depends on 
the patient’s general condition, and the size, location 
and number of metastases. It comprises enucleation, 
wedge excision of a fragment of the liver, excision of 
a segment/segments, non-anatomical resection or hemi-
hepatectomy. Resection of hepatic metastases of PNENs 
is considered only in cases of G1 and G2 neoplasms 
[113]. It depends on the resectability of the lymph 
nodes, lack of micronodular or non-resectable dissemi-
nation in the peritoneum, or distant metastases outside 
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of the abdominal cavity [113]. R2 resection should be 
considered in selected cases of functional neoplasms 
which do not respond to conservative treatment, in 
order to reduce the intensity of the symptoms (*evidence 
level 3). Excision of the primary tumour, lymph nodes 
and hepatic metastases, combined with thermoabla-
tion, may reduce the tumour mass by more than 90% 
[113]. In the case of unresectable metastatic lesions in 
the liver, cholecystectomy should be performed during 
surgery to prevent ischaemic complications of the gall 
bladder resulting from a possible implementation of 
(chemo) embolisation. Resection of hepatic lesions may 
be performed in one or two stages, depending on the 
location and size of the metastases [107]. Other methods 
of treating metastases include locoregional therapies 
(variants of ablation, embolisation) and liver transplan-
tation. It is assumed that transplantation is conducted in 
selected groups of patients with exacerbated symptoms 
associated with hormonal secretion. Patients who may 
benefit from transplantation are those under the age of 
50, without metastases outside the liver, and with a low 
expression of Ki-67 and E-cadherin [109].
If resection of hepatic metastases is impossible (un-
resectable or inoperable lesions), the recommended 
treatment methods include hepatic artery embolisa-
tion (HAE), transarterial chemoembolisation (TACE) or 
embolisation with the use of isotope (*evidence level 3). 
Currently, these methods are considered to be safe [14]. 
RFA, cryoablation and microwave ablation (MWA) can 
be used for tumours ≤ 5 cm [111].
In the case of a diagnosis of peritoneal dissemina-
tion, surgical treatment is controversial and is recom-
mended only in a selected group of patients. Even in 
some patients with unresectable liver disease, resection 
of the primary tumour together with macroscopic in-
traperitoneal nodules makes it possible to focus further 
therapies exclusively on the liver disease [114]. There is 
no consensus on the simultaneous resection of hepatic 
and intraperitoneal lesions. If an extensive surgery of 
the liver with resection of peritoneal lesions is neces-
sary, dividing the procedure into stages, conducting 
the resection in a specialist centre, and introducing 
multidirectional treatment should be considered. Pres-
ently, the combination of surgery and perioperative 
intraperitoneal chemotherapy, as well as intraoperative 
hyperthermic intraperitoneal chemotherapy (HIPEC) 
are in the experimental phase [114].
If tumour resection and the elimination of symptoms 
are not possible, a palliative surgical management is 
implemented, which can significantly affect the qual-
ity of life. This is used after exhausting all non-surgical 
methods, mainly when the tumour is responsible for 
mechanical jaundice, chronic pain and gastrointesti-
nal obstruction or bleeding. The treatment method is 
individualised for each patient. If mechanical jaundice 
occurs, it is recommended to perform anastomosis be-
tween the bile duct and intestine, or drainage of the bile 
tract. When an unresectable pancreatic tumour disturbs 
the passage of food through the duodenum, bypass 
surgery is recommended, usually a gastrointestinal 
anastomosis. The method of surgical management of 
chronic pain is coeliac plexus neurolysis and/or thora-
coscopic section of the splanchnic nerve. Treatment 
of patients with PNEN should be comprehensive and 
conducted by a multidisciplinary team of doctors; the 
surgery should be performed in a centre specialising in 
pancreatic surgery (*evidence level 3) [44].
Minimal consensus on surgical treatment
 — Accidentally detected non-functional neoplasms of ≤ 2 cm 
in diameter, without evidence of histopathological malig-
nancy may be observed, and the decision on the course of 
treatment should be taken by a multidisciplinary team 
of doctors experienced in the management of PNENs. 
Tumours of > 2 cm require an extensive surgery with 
lymphadenectomy. 
 — In certain cases of small (< 2 cm) and well-demarcated 
PNENs (non-functioning neoplasms and insulinomas), 
atypical resections may be performed, including enuclea-
tion and resection of the middle segment (it is necessary 
to collect the lymph nodes for histopathological examina-
tion). Distal resections and enucleations may be performed 
laparoscopically. 
 — Tumour resection should be considered even in the pres-
ence of metastases, including hepatic metastases, if they 
are potentially resectable and the patient meets the criteria 
for the surgery. It is believed that PNECs should not be 
operated if disseminated metastases have been found in 
the diagnostic process.
 — In advanced functioning PNENs, resection is intended to 
reduce the symptoms and the tumour mass. Cytoreduc-
tion may be considered when the removal of 90% of the 
tumour mass is possible, even if hepatic metastases are 
present (*evidence level 3).
 — In cases of unresectable hepatic metastases, the recom-
mended palliative treatments include HAE, TACE 
or embolisation with the use of a radioisotope. RFA, 
cryoablation and MWA can be used in tumours ≤ 5 cm 
(*evidence level 3).
Liver transplantation is conducted in a selected groups of 
patients with exacerbated symptoms associated with hormonal 
secretion. Patients who may benefit from the transplant are 
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those under the age of < 50 years, without metastases outside 
the liver, and with a low expression of Ki-67 and E-cadherin 
(*evidence level 3).
3.2. Endoscopic treatment of PNENs
The treatment of PNENs is generally surgical, and en-
doscopic management is only symptomatic.
Endoscopy may be used in the symptomatic treat-
ment of:
 — mechanical jaundice (prosthesis of the biliary duct);
 — obstruction of the gastrointestinal tract (prosthesis 
of the gastrointestinal tract lumen);
 — control of gastrointestinal bleeding (the use of en-
doscopic hemostatic methods).
 — EUS-controlled coeliac plexus neurolysis (CPN), 
described for the first time in 1996, involving admin-
istration of 0.25% bupivacaine solution, followed by 
98% alcohol, is an alternative method for the man-
agement of chronic pain associated with pancreatic 
tumours [115]. 
In recent years, single cases of using EUS for abla-
tion of F-PNETs secreting insulin have been reported 
[116–118]. It is possible that in the future endoscopic 
EUS-controlled ablation of PNETs, involving adminis-
tration of cytotoxic agents, alcohol or using thermoabla-
tion will become a therapeutic method for patients who 
cannot be treated surgically (*evidence level 4).
3.3. Medical treatment
The main purpose of pharmacological treatment is pre-
vention of the symptoms of the disease and maintaining 
the patient’s good quality of life (QoL) for the longest 
possible time [44]. Prior to planning the treatment, the 
tumour size, presence of metastases, histological grad-
ing and the profile of secreted peptides and markers 
should be determined (*evidence level 4).
The choice of the treatment method depends on 
the symptoms, staging of the disease, the level of radi-
otracer uptake in receptor scintigraphy and histological 
characteristics of the tumour [119] (*evidence level 4).
For non-surgical NENs, the goal of the treatment 
is alleviation of symptoms of the disease, maintain-
ing optimal QoL and, if possible, prolonged survival 
(*evidence level 5).
3.3.1. Symptomatic treatment
Symptomatic treatment should be started when the 
clinical and biochemical symptoms indicate hormonal 
activity of the NEN, even before the precise location 
of the primary site or confirmation of metastases. The 
symptoms associated with excessive secretion of hor-
mones by PNENs may impair the patient’s quality of 
life, and in certain cases they may be life-threatening 
(e.g. severe diarrhoea and hypokalaemia in VIPoma or 
carcinoid crisis). 
Pharmacological treatment mostly involves soma-
tostatin analogues and other medications, such as IPP 
in gastrinoma or diazoxide in the case of insulinoma. 
Additional symptomatic medications, such as lopera-
mide, cholestyramine and corticosteroids are used if 
necessary. Bisphosphonates can be used for pain man-
agement in patients with osseous metastases.
Functioning pancreatic neuroendocrine neoplasms 
(F-PNENs)
Somatostatin analogues (SSA)
Using somatostatin analogues (octreotide, lanreotide) 
is the ‘gold standard’ therapy of functioning PNENs, 
regardless of the tumour size [1, 120]. The recently 
published CLARINET study, involving 204 patients 
with GEP NENs (45% of patients with PNENs), also 
proved the antiproliferative effect of Lanreotide Autogel 
in a randomised, placebo-controlled phase III trial [121] 
(*evidence level 1).
New somatostatin analogues
SOM-230 (pasireotide) is a new analogue of somatosta-
tin (SSA). In phase II studies, pasireotide was used for 
symptomatic treatment in patients resistant to conven-
tional therapy (octreotide and lanreotide).
Interferon α
Interferon α is used in the treatment of both function-
ing and non-functioning NENs, in monotherapy or 
combined with long-acting SSA, if the patient does not 
respond to the treatment with maximum SSA doses. In-
terferon α may also be used in symptomatic treatment, 
but it is usually introduced as a second-line treatment 
due to its unfavourable toxicity profile [1]. Sometimes 
it is used as an adjuvant therapy in patients with clini-
cal syndromes which cannot be controlled with SSA.
Insulinoma 
Pharmacological treatment of insulinoma is intended to 
prepare patients for a surgical procedure, or to achieve 
biochemical control in patients with inoperable meta-
static insulinoma. Apart from frequent meals of small 
volume, patients require intravenous glucose admin-
istration. Despite this treatment, hypoglycaemia often 
requires additional medications to control the serum 
glucose concentration. In most patients with insulino-
ma, diaxozide has proved to be effective in controlling 
the symptoms of hypoglycaemia [4]. Diazoxide is used 
for short-term treatment of patients with insulinoma 
awaiting surgery, or for long-term treatment of patients 
with inoperable tumours. Diazoxide is an antihyper-
tensive medication with an additional hyperglycaemic 
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effect, as it inhibits insulin secretion by a direct action 
on pancreatic β cells and activation of glycogenolysis. 
The recommended daily dose is 50–300 mg orally, up 
to 600 mg/d. This is usually an effective treatment in 
controlling the symptoms of hypoglycaemia in patients 
with insulinoma. Adverse events, including oedema, 
increased body weight, hirsutism and renal function 
disorders are common, but usually tolerable. 
Diazoxide therapy is often supported with hydro-
chlorothiazide at a dose of 25 mg/day, which prevents 
oedema, hyperkalaemia and increases the hypergly-
caemic effect of diazoxide.
Verapamil and diphenylhydantoin (phenytoin) can 
be used to control glycaemia, as an alternative to diazox-
ide, in some patients with insulinoma. Corticosteroids, 
including prednisolone, are usually used in insulinoma 
patients resistant to the treatment of hypoglycaemia.
SSA (octreotide and lanreotide) are used in patients 
with confirmed somatostatin receptor type 2 expression 
on the tumour cells [119]. They are often ineffective in 
controlling hypoglycaemia (50–60% of insulinomas) 
and their effect on the blood glucose concentration 
varies [122]. In some cases, they may even intensify 
hypoglycaemia by inhibiting glucagon secretion [4, 123]. 
In some patients, using interferon α may be benefi-
cial in treating hypoglycaemia [34]. An mTOR inhibi-
tor — everolimus — is one of the medicines controlling 
insulin secretion and hypoglycaemia in patients with 
malignant insulinoma [4]. 
Gastrinoma
Pharmacological treatment of gastrinoma is dis-
cussed in the section on gastroduodenal NENs (pp. 
444–458).
VIPoma (symptoms: watery diarrhoea, hypokalaemia, 
achlorhydria (WDHA), Verner-Morrison syndrome)
Hydration and supplementation of electrolytes 
is recommended, as they may considerably improve 
the patient’s clinical condition. In patients with 
VIPoma, accompanied by a rare life-threatening syn-
drome, administration of SSA significantly relieves 
the symptoms (in 80–90% of patients) and lowers 
the concentration of vasoactive intestinal peptide 
(60–80%) [124]. Biochemical improvement does not 
always correlate with clinical improvement, so a 
dose titration based on patient’s clinical condition is 
necessary. Corticosteroids are used in patients with 
life-threatening diarrhoea which does not respond 
to the maximum doses of SSA.
Glucagonoma
Following introduction of SSA treatment, 80–90% of 
patients with glucagonoma demonstrate a visible clini-
cal improvement (reduced skin lesions due to necrolytic 
erythema), although the treatment is less effective in 
controlling diabetes and weight loss. SSA reduces 
blood glucagon concentration in approximately 60% 
of patients, although normalisation of this parameter 
is unlikely [125].
Zinc salts may be used in patients with glucagon-
oma to prevent further skin damage. Antithrombotic 
prophylaxis should be considered in all patients with 
NEN associated with an increased risk of thromboem-
bolic complications (e.g. glucagonoma).
Long-acting SSA are also effective in fighting the 
symptoms of ectopic hypersecretion in some cases of 
somatostatinoma [4]. They may also be useful in pa-
tients with paraneoplastic syndromes, e.g. Cushing’s 
syndrome and acromegaly, associated with ectopic 
secretion of ACTH or the growth-hormone-releasing 
hormone (GHRH).
In recent years, there has been growing interest 
in the use of glucocorticosteroid receptor antagonists, 
e.g. mifepristone, as well as dopamine agonists, e.g. 
cabergoline, in the treatment of Cushing’s syndrome. 
SSA have been proven effective in controlling hy-
percalcaemia associated with the hypersecretion of the 
parathyroid hormone-related peptide (PTHrP) in rare 
PNENs secreting PTHrH [126]. 
Non-functioning pancreatic neuroendocrine  
neoplasms (NF-PNENs)
Somatostatin analogues demonstrate antiprolifera-
tive effects, confirmed in patients with NENs. PROMID 
was the first phase III study, which revealed such effects 
of octreotide in the midgut tumours, both function-
ing and non-functioning ones [127]. In patients with 
PNENs, observational studies have demonstrated par-
tial or complete response in less than 10% of patients, 
and radiological stabilisation of the neoplasm in 24–57% 
of patients [128–130]. The results of the CLARINET 
phase III study have confirmed the antiproliferative 
effect of Lanreotide Autogel in patients with non-
functioning PNETs with low proliferation index (Ki-67 
< 10%) [121, 131]. 
3.3.2. Chemotherapy and targeted treatment
Chemotherapy is discussed in detail in section I of 
"Diagnostic and therapeutic guidelines for gastro-
entero-pancreatic neuroendocrine neoplasms 
(recommended by the Polish Network of Neuroen-
docrine Tumors)" (pp. 418–443)
Given the present state of knowledge, there is no evi-
dence that any adjuvant therapy (i.e. additional therapy 
after radical surgery) has a positive effect on extend-
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ing disease-free survival (DFS) and/or overall survival 
(OS) of patients with PNENs. This applies primarily to 
G1/G2 NENs [132]. In the case of neuroendocrine car-
cinoma (NEC), an adjuvant therapy based on platinum 
analogues should be considered. Although there are no 
phase III randomised prospective studies, it seems that 
chemotherapy including cisplatin (or carboplatin) with 
etoposide may prolong disease-free survival in patients 
with NECs (*evidence level 4). The use of adjuvant ra-
diotherapy or radiochemotherapy is not scientifically 
supported. 
In patients with advanced NECs, the basic therapy 
is chemotherapy including platinum analogues plus 
etoposide [132] (*evidence level 3).
The best results in the chemotherapy of advanced 
NENs have been achieved in G1/G2 NETs of pancreatic 
origin. The use of streptozotocin (STZ) in monotherapy 
resulted in a response rate (RR) of approximately 36%, 
and OS of ca. 17 months. Combining streptozotocin with 
5-fluorouracil (5-FU) increased the response rate to 63% 
and extended the mean overall survival to 26 months 
[133]. A breakthrough in chemotherapy of G1/G2 NENs 
was the phase III study by Moertel et al. in 1992 [134], in 
which 69 patients were randomised to two chemotherapy 
arms: streptozotocin-based, i.e. with doxorubicin (DOX) 
v. chemotherapy with 5-FU, demonstrating RR of 69% v. 
45%, respectively, with the mean clinical response time of 
18 months v. 14 months, and the mean overall survival of 
26 months v. 17 months (*evidence level 3). 
The effectiveness of the chemotherapy of well/me-
dium-differentiated GEP NENs should be considered 
separately for neoplasms of pancreatic origin and those 
with different locations (stomach, duodenum, small 
intestine, appendix and colon). Indirect comparisons 
of the results of clinical studies involving patients with 
GEP NENs have demonstrated a higher probability of 
response in patients treated due to PNENs (15–35% 
compared to 5–15%) [135]. 
In well-differentiated PNENs, the highest activity in 
monotherapy (response rate: 20–40%) is demonstrated 
by streptozotocin, doxorubicin, fluorouracil, dacar-
bazine and temozolomide. Multi-drug regimens are 
more effective then monotherapy regarding the effect 
on the response and survival rates (mean survival — 
15–30 months). 
The expert panel recommends combining streptozo-
tocin (the medicine is not registered in Poland, available 
as direct import) with doxorubicin and 5-fluorouracil, 
and using a two-drug chemotherapy in patients with 
a greater risk of complications or not qualifying for the 
treatment with anthracyclines. 
3.2.3. New targeted therapies [44]
In patients diagnosed with advanced PNENs (locally 
advanced stage, without a possibility of surgical 
treatment and disseminated stage), it is now possi-
ble to use molecularly targeted drugs (sunitinib and 
everolimus) in the case of progression of the disease 
(progression within the last 12 months assessed on 
the basis of imaging examinations results and the 
RECIST classification). Sunitinib is indicated in the 
case of well-differentiated neoplasms (NENG1), and 
indications for everolimus comprise well- and moder-
ately-differentiated neoplasms (NENG1 and NENG2) 
[136, 137]. These medications — everolimus (a serine/ 
/threonine kinase — mTOR — inhibitor) and sunitinib 
(a tyrosine-kinase inhibitor) [138] significantly extend 
progression-free survival (PFS) by approximately 
5.5–6 months. Adding everolimus to octreotide (the 
RADIANT-3 trial) extended progression-free survival 
by approximately five months (16.4 v. 11.3) compared 
to monotherapy with SST analogue.
In patients with malignant insulinomas resistant to 
conventional treatment, using everolimus significantly 
improved the control of glycaemia [139, 140].
Everolimus and sunitinib may, in justifiable cases, 
be used as the first-line treatment in patients with ad-
vanced well-differentiated PNENs (documented radio-
logical progression within 12 months) (*evidence level 1).
Using sunitinib and everolimus is associated with 
a number of unresolved problems (e.g. the order of use 
for various treatment methods, selection of patients for 
specific medications, the ability to anticipate effective-
ness, and adverse reactions). The value of sunitinib 
and everolimus in poorly differentiated PNECs, and 
the possibility of combining them with other methods 
(e.g. adjuvant postsurgical treatment) also require 
clarification.
The effectiveness of pazopanib (another multikinase 
inhibitor), demonstrated in the phase II studies, needs 
to be confirmed, which is particularly important due to 
a generally better tolerance of the treatment.
Minimal consensus on the medical treatment in 
pancreatic NENs
Functioning G1/G2 PNENs — somatostatin analogues (*evi-
dence level 1), and in the case of progression of the disease, 
adding everolimus (*evidence level 1).
Advanced non-functioning G1/G2 PNENs — systemic 
chemotherapy including streptozotocin with doxorubicin 
(± 5-FU) (*evidence level 3) and/or a somatostatin analogue 
(*evidence level 1). If the disease progresses after chemo-
therapy, everolimus or sunitinib (*evidence level 1). Targeted 
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therapy can be considered as first-line therapy in selected cases 
as an alternative treatment to chemotherapy.
The basic treatment of PNEC is chemotherapy based on the 
cisplatin plus etoposide regimen (*evidence level 3). 
3.4. Radioisotope treatment
Isotope therapy with labelled SSA (PRRT, peptide 
receptor radionuclide therapy) is now becoming a rec-
ognised form of palliative treatment, giving a chance 
for stabilisation or partial regression of the neoplastic 
disease, and less often for a complete remission [141, 
142]. De Jong et al. [141] in 1998 published the results 
of a multicentre study involving a group of 256 patients 
with GEP NENs, including PNENs, treated with 90Y 
DOTA TOC. 
In 27% of the patients, a partial response to the 
treatment was observed, and in individual cases 
a total response was achieved. The results of the 
90Y/177Lu DOTA TOC therapy in a group of 20 pa-
tients, including 15 with PNEN, were presented in 
2006. Regarding the patients with PNEN, the authors 
observed stabilisation of the disease in eight patients, 
partial remission in four patients, and progression of 
the disease in three patients [143]. Presently, more 
common in PRRT is [Tyr3]octreotate (DOTA TATE), 
an analogue which demonstrates a higher affinity to 
SSTR2 than the previously used ones. The therapy 
has been successfully conducted in a few centres in 
Poland, also in patients with PNENs, after confirm-
ing a high somatostatin receptor expression in the 
primary/meta tumour in SPECT or PET examination. 
It is now believed that, similarly to GEP NEN of 
different locations, the therapy may be introduced 
without a prior chemotherapy. Based on the observa-
tions in patients treated with chemotherapy before 
the isotope treatment, is has been established that 
myelotoxicity and nephrotoxicity occur more often. 
Similarly to other GEP NENs, the main indica-
tions for the treatment of PNEN with labelled SSA 
are advanced and inoperable NENG1 or NENG2. In 
individual cases, this therapy may be used in NEC with 
a sufficient somatostatin receptor expression, especially 
if the disease progresses and other treatment options 
have been exhausted [2, 4, 34]. Isotope therapy may be 
considered in the case of non-surgical recurrence and 
primarily, as a form of neoadjuvant treatment if surgi-
cal management is impossible due to a significant local 
advancement of the tumour [144]. Recent reports point 
to the possibility of using PRRT much earlier, before 
the surgery of unresectable lesions, mostly in the case 
of PNENs. The authors used both 90Y and 177Lu isotope 
combined with a SSA. Among the patients receiving 
PRRT as noeoadjuvant treatment of an inoperable 
primary tumour, there were single cases of patients 
with hepatic metastases, in whom the isotope therapy 
resulted not only in regression of the tumour mass, 
but also of the metastatic lesions [145, 146]. Due to 
a limited group of patients receiving this form of treat-
ment, there is no strong evidence for introducing PRRT 
prior to a non-surgical procedure in the management 
guidelines; however, this form of treatment may be 
individually considered, depending on the patient’s 
clinical condition, advancement of the disease and the 
proliferation index of the neoplasm. Each time while 
deciding on the isotope treatment, adverse reactions as-
sociated with this form of therapy should be taken into 
account. In the case of PNENs with insufficient SSTR2 
expression, indications for the 90Y and 177Lu DOTA TATE 
therapy may be limited. In overexpression of SSTR5, 
another radiotracer, i.e. 90Y DOTA LAN may be used 
[34]. Expression of this type of receptor may also be 
present in well-differentiated neoplasms, especially 
those which lost the active SSTR2 during therapy, as 
a result of treatment with SSA (tachyphylaxis) [34]. 
PRRT may also be used to treat functioning PNENs. 
In the case of malignant lesions, it is possible to 
conduct isotope treatment [10, 34] as a form of pal-
liative management with temporary therapeutic 
response. In patients with diffuse gastrin tumour and 
positive receptor scintigraphy results, eligibility for 
PRRT should be considered. However, similarly to 
other PNENs, this therapy requires studies involving 
a larger number of patients in order to establish its 
actual therapeutic value [104]. Based on individual 
reports in the literature, it is known that gastrinomas 
respond to therapy faster, but early progression is 
relatively frequent [34]. 
The treatment with ‘hot’ SSA is a relatively new form 
of therapy, used mainly as palliative treatment, with-
out any expectations regarding the impact on partial 
remission of the disease or the patient’s survival. Some 
new publications have indicated a possibility of using 
PRRT as second-line therapy in the case of disease pro-
gression, following stabilisation or remission achieved 
with this method. It appears that re-implementation of 
isotope treatment at the maintained expression of so-
matostatin receptors may prolong the patient’s survival 
without a significant exacerbation of adverse reactions 
associated with this therapy [147]. Radioisotope treat-
ment is frequently combined with ‘cold’ SSA (including 
non-functioning neoplasms). Monitoring of the effects 
of PRRT comprises not only imaging examinations, 
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but also monitoring of CgA and the markers specific 
for functioning PNENs. In PNEN, CgA is a prognostic 
factor of PFS [148].
Among different forms of PRRT in NETs, includ-
ing PNENs, radioembolisation with yttrium-labelled 
microspheres is used, in which the response rate 
is estimated at 52–66% and the mean survival is 
70 months [149, 150]. According to Ramage et al. [151], 
a complete remission of the disease is achieved in 
2.7% of patients, and a partial remission in 60%. Since 
there are no reports on the use of radioembolisation 
in a larger group of patients, further studies in this 
field are necessary.
Position of PRRT in the management of PNENs
In both functioning and non-functioning PNENs, 
the basic form of treatment is surgery. In the case of 
advanced disease and non-functioning neoplasms, 
the treatment with labelled somatostatin analogues 
may be considered as the first-line therapy of disease 
progression, preceding other forms of management. 
Chemotherapy may be introduced as the second-line 
treatment if the disease progresses, especially when 
SSTR expression is lost. 
The next stage in the management of secreting tu-
mours progressing after the surgical treatment is using 
‘cold’ SSA. Isotope treatment should be considered as 
the second-line treatment. 
Minimal consensus on PRRT
PRRT may be used in advanced, inoperable PNENs, especially 
G2 and G1 (*evidence level 3). PRRT may be considered in 
individual cases with NEC, provided a high somatostatin 
receptor expression is confirmed and other forms of therapy 
prove ineffective (*evidence level 4). 
In functioning neoplasms of the pancreas, PRRT as the 
second line treatment, after a ‘cold’ SSA (*evidence level 3). 
In non-functioning tumours of the pancreas, PRRT may 
be considered as the first-line therapy, preceding other forms 
of palliative treatment (*evidence level 4).
In both cases, surgical management is the basic form of 
treatment.
5. Follow-up
This is discussed in detail in section I of "Diagnostic 
and therapeutic guidelines for gastro-entero-pancreatic 
neuroendocrine neoplasms (recommended by the Pol-
ish Network of Neuroendocrine Tumors)" (pp. 418–443).
Minimal consensus on follow-up
Monitoring of the treatment should be individualised accord-
ing to histological differentiation of the NEN (G1, G2 or G3) 
and the disease staging. 
Follow-up comprises clinical examination, determination 
of the concentration of CgA and specific markers (in function-
ing neoplasms, depending on the clinical symptoms), as well 
as radiological (USG, CT/MRI), endoscopic and functioning 
(SRS) examinations. The frequency of examinations depends 
on the stage of the disease (2–3 months for NECs and 6–12 
months for G1 and G2 PNETs).
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